Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked recessive disorder characterized by severe intellectual disability, dystonia, and alterations in thyroid hormone metabolism. The syndrome results from mutations in the SLC16A2 gene (also known as MCT8), which encodes a monocarboxylate transporter responsible for transporting thyroid hormones across the cell membrane. This condition primarily affects males and is considered a member of the thyroid hormone resistance syndromes.
AHDS is caused by loss-of-function mutations in the SLC16A2 gene (solute carrier family 16 member 2) located on chromosome Xq13.2. The gene encodes the thyroid hormone transporter MCT8 (monocarboxylate transporter 8), which is essential for the cellular uptake of active thyroid hormones T3 (triiodothyronine) and T4 (thyroxine).
- X-linked recessive inheritance
- Primarily affects males
- Female carriers may exhibit mild thyroid dysfunction but are usually asymptomatic
- De novo mutations account for approximately 25% of cases
Over 70 pathogenic variants have been identified, including:
- Missense mutations (most common)
- Nonsense mutations
- Frameshift mutations
- Splice site mutations
MCT8 is expressed in various tissues, including:
The loss of functional MCT8 transporter leads to:
- Impaired neuronal thyroid hormone uptake — neurons cannot efficiently import T3, despite normal or elevated serum T3 levels
- Elevated serum T3 — due to impaired cellular uptake and increased peripheral conversion
- Reduced cerebral T3 — leading to impaired brain development and function
- Abnormal thyroid function tests — elevated T3, normal or reduced T4, normal TSH
The thyroid hormone deficiency in the brain during critical developmental periods results in:
- Impaired neuronal migration
- Abnormal cortical development
- Disrupted myelination
- Altered synaptic plasticity
- Abnormal basal ganglia development (particularly affecting the globus pallidus)
- Severe intellectual disability — IQ typically below 40
- Dystonia — progressive movement disorder, often beginning in childhood
- Ataxia — impaired coordination
- Hypotonia — decreased muscle tone in infancy
- Seizures — observed in approximately 30% of patients
- Delayed motor milestones
- Speech impairment — most patients remain non-verbal
- Microcephaly — small head circumference
- Facial dysmorphism — including elongated face, prominent ears, and nasal abnormalities
- Skeletal abnormalities — including kyphosis and joint contractures
- Growth retardation
- Elevated serum T3
- Normal or reduced T4
- Normal TSH (euthyroid)
- Inappropriately normal TSH despite elevated T3
Based on:
- Clinical features (intellectual disability, dystonia, characteristic thyroid function abnormalities)
- Family history (X-linked pattern)
- Genetic testing confirming SLC16A2 mutation
- Elevated serum T3 (often 2-3x normal)
- Normal or reduced free T4
- Normal TSH
- Normal thyroid antibodies (ruling out autoimmune thyroiditis)
- SLC16A2 sequencing — identifies pathogenic variants
- Multiplex ligation-dependent probe amplification (MLPA) — detects large deletions/duplications
- MRI findings may include:
- Cerebral atrophy
- Abnormal signal in the globus pallidus
- Delayed myelination
- Cerebellar atrophy (in some cases)
- Thyroid hormone therapy — supraphysiological doses of T4 may provide some benefit
- T3 supplementation — experimental approaches to bypass the transport defect
- Dystonia management — baclofen, botulinum toxin injections, physical therapy
- Antiepileptic drugs — for seizure control
- Supportive care — speech therapy, occupational therapy, special education
- Gene therapy — experimental approaches to restore MCT8 function
- Thyroid hormone analogs — such as diiodothyropropionic acid (DITPA) that can enter cells via alternative transporters
- Cell-based therapies — under investigation
- Neurology
- Endocrinology
- Genetics
- Developmental pediatrics
- Physical/occupational therapy
- Speech therapy
- Understanding MCT8 substrate specificity — to develop targeted therapies
- Gene therapy vectors — for efficient delivery to neurons
- Thyroid hormone analog development — to bypass the transport defect